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Abstract
Alternative splicing of pre-mRNA is a process in which noncoding regions of primary transcript are removed and coding regions are
joined in different manners to produce mRNA molecules of different sequences. Alternative splicing affects nearly all human genes and is
a key source of diversity of proteins coded by a relatively small number of genes. Since alternative splicing is of crucial importance for the
proper functioning of cells, including those involved in hormonal signalling, aberrations of alternative splicing can lead to disruption of
cellular mechanisms and in consequence result in serious endocrine pathologies. Disturbances of alternative splicing include mutations of
consensus splice regulatory sites and improprieties in the action of splicing factors, the proteins involved in regulating the process. In
consequence of disturbed alternative splicing, improperly spliced mRNA and protein isoforms can be produced which can lead to disrup-
tion of function of their wild type counterparts.
This review aims to discuss the role of alternative splicing in pathologies of the endocrine system and gives examples that highlight the
importance of this process in the proper functioning of hormones, hormone receptors and other factors involved in hormonal regulation.
The examples given include endocrine-related tumours (pituitary tumours, cancers of the thyroid, prostate, ovary and breast, and insuli-
noma), isolated growth hormone deficiency, and Frasier syndrome. Non-endocrine pathologies in which aberrant alternative splicing of
transcripts of genes involved in hormonal signalling have been detected are also described. Finally, we discuss future perspectives on the
possible usage of alternative splicing in diagnostics and therapy.
(Pol J Endocrinol 2011; 62 (2): 160–170)
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Streszczenie
Różnicowe składanie pierwotnego transkryptu (splicing alternatywny pre-mRNA) jest procesem polegającym na usuwaniu rejonów, które
nie kodują dojrzałej cząsteczki mRNA (intronów) i łączeniu rejonów kodujących (eksonów) w różnych konfiguracjach, dzięki czemu
powstają cząsteczki mRNA o różnej sekwencji nukleotydów. Różnicowemu składaniu podlegają transkrypty prawie wszystkich kodują-
cych białka genów człowieka, przyczyniając się do powstawania wielkiej różnorodności izoform białek kodowanych przez stosunkowo
niewielką liczbę genów. Proces splicingu alternatywnego w istotny sposób przyczynia się do prawidłowego funkcjonowania komórek,
również tych biorących udział w sygnalizacji hormonalnej. Zaburzenia różnicowego składania pre-mRNA prowadzą do nieprawidłowo-
ści w procesach komórkowych i w konsekwencji mogą prowadzić do zaburzeń endokrynnych. Zaburzenia różnicowego składania pre-
mRNA wynikają z mutacji w tak zwanych miejscach splicingowych bądź z nieprawidłowego działania czynników splicingowych, czyli
białek zaangażowanych w regulację tego procesu.
Niniejsza praca ma na celu przedstawienie roli różnicowego składania pre-mRNA w patologiach układu endokrynnego, takich jak nowo-
twory endokrynne (guzy przysadki, rak tarczycy, prostaty, jajnika, piersi, insulinoma), izolowany niedobór hormonu wzrostu, dysgenezja
gonad. Omówione zostały także przykłady patologii niezwiązanych bezpośrednio z układem endokrynnym, w których wykryto zabu-
rzenia alternatywnego splicingu transkryptów genów biorących udział w sygnalizacji hormonalnej. Artykuł kończy przegląd możliwości
diagnostycznych i terapeutycznych w chorobach endokrynnych, wykorzystujących proces różnicowego składania pre-mRNA.
(Endokrynol Pol 2011; 62 (2): 160–170)
Słowa kluczowe: różnicowe składanie pierwotnego transkryptu, nowotwory endokrynne, izolowany niedobór hormonu wzrostu, zespół Frasiera
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Alternative splicing: basis of the process
The majority of human genes encoding proteins con-
sist of regions which do not code for the mature tran-
script (introns) and regions of coding sequences (exons).
During the synthesis of RNA, both kinds of sequenc-
es are transcribed into the primary transcript (pre-
mRNA). Splicing is the process in which introns are re-
moved and exons are joined to produce an mRNA mol-
ecule which can be further translated. Exons, however,
can be joined in different ways. As a result of this pro-
cess, multiple mRNA and protein isoforms are produced
from a relatively small number of genes (in human ge-
nome: ~25,000). Alternative splicing affects the vast
majority of human genes (more than 90%) [1] and is
one of the main sources of protein diversity, allowing
for the synthesis of multiple isoforms of receptors, ad-
hesion molecules, protein hormones etc.
Alternative splicing is a complicated process, involv-
ing specific consensus sequences in exons and introns
of primary transcript and multiple regulatory proteins.
The sequences include 3’ splice site (3’ss), polypyrymi-
dine tract, branch point sequence (BPS), and 5’ splice
site (5’ss) (Fig. 1A.). Splicing reactions result in different
types of mRNA isoforms due to differential usage of
splice sites, exclusion/inclusion of exons or even intron
retention (Fig. 1B.). The process of splice site selection
during alternative splicing is supported by auxiliary
Figure 1. Basis of alternative splicing. A. Consensus sequences participating in alternative splicing include 5’ and 3’ splice sites, branch
point, and polypirymidine tract. B. Types of alternative splicing (starting from left, clockwise): inclusion/exclusion of exons (here: of
exon 2, shown with an arrow); mutually exclusive exons (here: exons 2 and 3); usage of alternative 3’ splice sites (shown with an arrow);
retention of an intron (shown with an arrow); usage of alternative 5’ splice site (shown with an arrow)
Rycina 1. Różnicowe składanie pierwotnego transkryptu. A. Sekwencje nukleotydów biorące udział w składaniu pre-mRNA: miejsca
splicingowe 5' i 3', punkt rozgałęzienia (branch point) i trakt polipirymidynowy. B. Rodzaje różnicowego składania pre-mRNA
(rozpoczynając od lewej, zgodnie z ruchem wskazówek zegara): włączanie/wyłączanie eksonów (tutaj: eksonu 2, wskazanego strzałką);
wzajemnie wykluczające się eksony (tutaj: eksony 2 i 3); wykorzystanie alternatywnych miejsc 3' splicingowych (miejsce wskazano
strzałką); zatrzymanie intronu (wskazany strzałką); wykorzystanie alternatywnych miejsc 5' splicingowych (miejsce wskazano strzałką)
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sequences of exonic and intronic splicing ehancers (ESEs
and ISEs, respectively), and exonic and intronic splic-
ing silencers (ESSs and ISSs, respectively).
Splicing reactions are catalysed by spliceosome,
a large complex formed by five small ribonucleopro-
teins (snRNAs: U1, U2, U4, U5, and U6) and more than
300 other proteins. Alternative splicing is strictly regu-
lated by a number of splicing factors, including SR pro-
teins (serine-arginine rich proteins) [2] and hnRNPs
(heterogeneous nuclear ribonucleoproteins) [3].
Binding of these regulatory proteins to ESE/ISE se-
quences (in the case of SR proteins) or to ESS/ISS (in the
case of hnRNPs) defines selection of specific splice sites
and thus selection of exons included in the spliced
mRNA [4]. The selection of splice sites is also influenced
by relative levels of specific splicing factors binding to
the regulatory sequences. In consequence, the final re-
sult of alternative splicing is an effect of the concerted
action of antagonistically acting splicing factors.
 Disturbances of alternative splicing are frequently
observed in different types of pathologies, including
neurological disorders [5], inherited metabolic diseases
[6], and cancer [7, 8]. Improperly spliced mRNA iso-
forms, if translated, may lead to synthesis of proteins of
altered sequence, length, and structure. This may lead
to malfunction of proteins, disturbances of cellular
physiology, and finally to disease. Disturbances of al-
ternative splicing may result from mutations in splice
sites or cis regulatory elements, or from altered func-
tion of spliceosome elements.
Mutations in splice sites and other consensus se-
quences lead to missplicing, exon skipping, activation
of cryptic splice sites or retention of intron. Mutations
in splicing silencers or enhancers change the repertoire
of splicing factors recognising the regulatory sequence
and in this way influence splice site selection, leading
to synthesis of improperly spliced mRNAs.
Since relative levels of antagonistic splicing factors
influence the selection of splice sites, disturbances of
expression of splicing factors play a significant role in
pathologies associated with impaired splicing. An ex-
ample is splicing factor SF2/ASF, a member of the SR
protein family, whose overexpression is often observed
in cancers. SF2/ASF regulates alternative splicing of tu-
mour suppressor Bin1. Inclusion of exon 12A into Bin1
transcript, caused by overexpressed SF2/ASF, leads to
loss of its tumour suppressive activity [9].
Alternative splicing is a process affecting genes in-
volved in all human physiological systems. The role of
alternative splicing in the physiology of the endocrine
system was set out more than a decade ago in two ex-
cellent reviews [10, 11].
This review aims to discuss the role of alternative
splicing in pathologies of the endocrine system and
gives several examples that highlight the importance
of this process in the proper functioning of hormones,
hormone receptors and other factors involved in hor-
monal regulation.
Endocrine-related tumours
Disturbances of alternative splicing are especially fre-
quently observed in cancers [7]. Improperly spliced
mRNA isoforms and aberrantly acting splicing factors
are therefore also found in endocrine-related tumours.
Pituitary tumours
Thyrotropin-secreting pituitary adenomas (TSH-omas)
are rare pituitary tumours accounting for less than 2%
of pituitary tumour cases [12]. These tumours lead to
disruption of the negative feedback system of the hy-
pothalamus-pituitary-thyroid (HPT) axis, resulting in
elevated free T3 and T4 in serum with concurrent high
levels of serum TSH. The molecular basis of TSH-omas
etiology is not well understood, although some obser-
vations of chromosomal and genetic aberrations have
been described [12]. Since one of the features of TSH-
omas is the block of thyroid hormone mediated inhibi-
tion of TSH secretion in the pituitary, several studies
have tried to analyse possible alterations in the func-
tion of thyroid hormone receptors (TRs). Those studies
led to identification of an improperly alternatively
spliced variant of thyroid hormone receptor beta 2
(TRb2spl) in TSH-oma [13]. TRb2spl lacked more than
40 amino acids in the ligand binding domain of the re-
ceptor, substituted with single amino acid isoleucine,
resulting in complete loss of T3 binding, as well as the
ability to interact with co-repressors and coactivators.
Moreover, as DNA binding domain of the receptor was
not changed, TRb2spl exerted a dominant negative activ-
ity. Those functional improprieties resulted in loss of
T3-dependent regulation of TSH expression and secretion.
In the THRB gene coding the receptor, no mutations were
detected, suggesting that abnormal alternative splicing
was a result of malfunction of splicing factors.
The agonists of dopamine receptors (DRs) are used
for the treatment of pituitary tumours to achieve re-
duction of hormone release and tumour size [14]. How-
ever, a significant number of patients do not respond
to this treatment. Several studies have suggested that
this lack of response may be, at least partially, connect-
ed with the expression of alternatively spliced isoforms
of DR2 receptor: DR2S and DR2L. DR2S is the shorter
isoform which is devoid of exon 5 encoding 29 amino
acids in the third cytoplasmic loop involved in G pro-
tein coupling [14]. The expression of the two variants is
heterogenous in pituitary adenomas, ranging from the
equal level of DR2S and DR2L [15], or different ratios of
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DR2L to DR2S [16–18] to a complete loss of DR2 recep-
tor [16, 17]. The specific ratios of DR2 isoforms may in-
fluence patient response to dopamine agonists. Studies
on nonfunctioning adenoma-derived cell lines revealed
that treatment with the dopamine agonist, bromocrip-
tine, led to inhibition of proliferation in cells expressing
only DR2S or in cells in which the expression of DR2S
was predominant [16]. Those initial ex vivo experiments
were subsequently confirmed by studies on pituitary
tumour samples. High expression of DR2S was associ-
ated with better response to treatment with bromocrip-
tine in prolactinomas [19] and with cabergoline in NFPA
tumours [17]. This beneficial effect of DR2S variant may
result from differential induction of intracellular signal-
ling when compared to DR2L. This hypothesis is sup-
ported by the observation that while stimulation of both
receptors leads to an increase of free calcium in cytoplasm,
DR2S is more effective in inhibition of cAMP accumula-
tion than DR2L [20]. Moreover, the two isoforms differ
in inhibitory effects on ERK1/2 signaling [21].
Thyroid cancer
Considering the frequency of disturbed alternative
splicing events in cancers, surprisingly few papers have
reported alterations of this process in thyroid neopla-
sia. Papillary thyroid carcinomas (PTCs) are character-
ized by high frequency of mutations in BRAF oncogene
[22]. Baitei et al. [23] identified in PTCs, follicular vari-
ants of PTCs (FVPTCs), and in one case of anaplastic
thyroid carcinoma (ATC) splice variants of BRAF which
coded for a variant of B-Raf protein which was devoid
of N-terminal auto-inhibitory domain but contained
C-terminal kinase domain and caused constitutive acti-
vation of B-Raf. Those splice variants, when expressed
in cell lines, resulted in activation of MAP kinase sig-
nalling pathway, tumoural transformation of cells and
induction of tumours in nude mice [23] suggesting that
disturbance in alternative splicing of BRAF may direct-
ly contribute to development of PTC tumours.
Differences in expression of splice variants can serve
as markers for differentiation between malignant and
benign nodules as shown in the study analysing telom-
erase reverse transcriptase (hTERT) [24]. Malignant thy-
roid tumours, irreversibly of the histopathological type
(with the exception of follicular variants of papillary
thyroid cancer), were characterized by higher expression
of active full-length hTERT transcript than of inactive
splice variants which were devoid of regions a and/or b.
In another report, in 18 per cent of analysed PTC
samples, expression of MDM4-211 splice variant of
MDM4 protein, an inactivator of p53 tumour suppres-
sor, was detected [25]. MDM4-211 was not expressed in
non-tumourous paired controls. Since it was shown that
MDM4-211 exerts oncogenic potential [26], its overex-
pression may contribute to tumoural transformation in
certain cases of PTC.
The causes of aberrant alternative splicing of thy-
roid cancers are usually unknown. The exception is
a study of a family with hereditary goitrous hypothy-
roidism and metastatic thyroid carcinoma in which ab-
errant splicing of thyroglobulin (Tg) was detected [27].
The patients had an autosomal recessive mutation in
the splice donor site of intron 5 of Tg gene which re-
sulted in the frame shift and a premature stop codon at
position 147. The authors suggested that the malignant
transformation could possibly result from prolonged
TSH stimulation. In cases when no splice disturbing
mutations are known, a possible cause could be aber-
rant expression of splicing factors such as SF2/ASF
whose overexpression was found in follicular thyroid
carcinoma [9]. However, it is clear that more studies on
thyroid tumours are needed to reveal to what level dis-
turbances of alternative splicing contribute to patholo-
gy of this type of neoplasia.
Prostate and ovarian cancers
Krüppel-like factors (KLFs) are transcription factors
whose dysregulated activity was suggested to be linked
with endocrine-related malignancies [28]. Specific splice
isoforms of one of the members of this family, KLF6,
play a direct role in carcinogenesis. Splice variant KLF6-
SV1 is an oncogenic isoform which antagonises tumour-
suppressive properties of KLF6 variant [29]. The iso-
forms differ in their structure: KLF6-SV1 lacks zing fin-
ger DNA binding domain, while in KLF6 this domain is
present. In a study involving more than 3,400 men it
was found that a germline single nucleotide polymor-
phism (SNP) in KLF6 is associated with an increased
risk of prostate cancer [30] (Fig. 2A). This SNP resulted
in the generation of a novel binding site for splicing fac-
tor SRp40 which shifted splicing reaction into increased
synthesis of three KLF6 spliced isoforms, including
KLF6-SV1. In hormone-refractory metastatic prostate
cancer, the levels of KLF6-SV1 were upregulated. In
human prostate cancer cell lines overexpression of
KLF6-SV1 led to increased proliferation due to down-
regulation of cyclin-dependent kinase inhibitor p21 and
upregulation of antiapoptotic Bcl-2, and of oncogenic
c-myc. Overexpression of KLF6-SV1 was also followed
by and enhanced expression of metalloproteinase
MMP9 which is involved in tumour cell migration and
invasion [30]. Those observations were completed by
mouse models of metastatic prostate cancer in which
overexpression of KLF6-SV1 led to more rapid metasta-
sis and dissemination to lymph nodes, bone, and brain.
Similar effects were observed in ovarian cancer cells [31]
in which overexpressed KLF6-SV1 bound a proapop-
totic protein NOXA and induced its degradation
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through HDM2 ubiquitin ligase mediated mechanism.
NOXA acts as a binding partner for Mcl-1, which is
a member of an antiapoptotic Bcl-2 family. Binding of
Mcl-1 by NOXA inhibits its antiapoptotic activity.
KLF6-SV1-induced degradation of NOXA leads to up-
regulation of Mcl-1 and this way contributes to survival
of cancer cells (Fig. 2A).
Results of studies on prostate and ovarian cancer
suggest that KLF6-SV1 targeting offers an approach for
treatment of these cancers. RNAi mediated downregu-
lation of KLF6-SV1 leads to spontaneous apoptosis in
cultured prostate cancer cell lines and suppresses tumour
growth in mice [32, 33]. Silencing of KLF6-SV1 in ovari-
an cancer cells induces spontaneous apoptosis, restores
cisplatin sensitivity, decreases tumour progression, and
improves survival in mice [31]. Since disturbed alterna-
tive splicing of KLF6 has been observed in many other
cancers, including pancreatic [34], gastric [35], liver [36],
and other [37, 38, 39], targeting of KLF6 alternative splic-
ing may be a more generalised strategy to fight cancer.
Insulinoma
Alternative splicing can lead to synthesis of different
mRNA isoforms which are translated into proteins of
identical amino acid sequence. An example is alterna-
tive splicing of proinsulin whose alternatively spliced
variants NAT and SPV differ in their 5’ untranslated
regions (5’UTRs) [40] (Fig. 2B). UTRs are regulatory re-
gions of mRNA molecules involved in the regulation of
mRNA stability, cellular localization and translational
efficiency [41]. Variant SPV of proinsulin is synthesised
due to retention of intron 1 which leads to change of
5’UTR sequence but leaves the coding region of mRNA
unchanged (Fig. 2B). This splice variant accounts for less
than 1% of native insulin mRNA in normal pancreatic
islets [40]. The change in 5’UTR of SPV variant results in
doubling the efficiency of translation, yielding more
(pre)proinsulin protein. In insulinoma tumours, dis-
turbed alternative splicing of proinsulin leads to a dra-
matic, greater than 50-fold, increase of SPV : NAT ratio
[42]. This in turn results in enhanced synthesis and se-
cretion of insulin, leading to hyperinsulinemia.
Breast cancer
In breast cancers disturbed alternative splicing of mul-
tiple endocrine system related genes have been detect-
ed, including altered splicing of oestrogen, thyroid hor-
mone, and progesterone receptors (ER, TR, and PR, re-
spectively). All these receptors belong to the nuclear
receptor family and act as ligand dependent transcrip-
tion factors. Several studies have suggested that the
expression of oestrogen receptor splice variant ERbcx
may influence disease progression in breast cancer pa-
tients [43]. Loss of ERbcx was correlated with more ag-
gressive phenotype, increased risk of vascular invasion
[44], higher number of affected lymph nodes, and in-
creased risk of developing metastatic breast cancer [45].
ERbcx expression was associated with response to en-
docrine therapy and/or survival in breast cancer patients
[46–49]. ERbcx (also known as ERb2) differs from the
ERb1 variant by the sequence of amino acids in AF-2
(activation function) domain which is essential for
ligand-dependent transcriptional activation. ERbcx is
devoid of ligand binding ability but binds to DNA in
heterodimers with ERa or ERb1 isoforms. Binding of
ERbcx in complex with ERa leads to an inhibition of its
transcriptional activity, while binding with ERb1 does
not influence the activity of the latter. Thus, ERbcx acts
as a dominant negative inhibitor of ERa. Therefore, ex-
pression of ERbcx in ERa-positive breast cancers has the
potential to modulate the response to antioestrogen
therapy. As suggested by Palmieri et al. [46], ERbcx
mediated blockade of ERa activity could synergise with
actions of antioestrogens such as tamoxifen, used in
anticancer therapy, and thus may provide a beneficial
effect for patients [46]. Other studies on the role of ERbcx
in breast cancer, however, have provided conflicting
results. For instance, in one study no connection be-
tween ERbcx protein status and patient survival was
found [50]. In other studies, cytoplasmic ERbcx expres-
sion correlated with poor prognosis [49, 51], while nu-
clear positivity of ERbcx was shown to correlate with
overall survival and disease-free survival [49]. In other
reports, ERbcx expression did not have the predictive
value on tamoxifen resistance [52] or correlated with
poor response to this drug [44]. On the other hand, in
the study by Vinayagam et al. [53], a positive correla-
tion between tamoxifen-therapy outcome and ERbcx
mRNA but not protein level was found, and especially
good results of the therapy were achieved in patients
who expressed high levels of both protein and mRNA
of ERbcx. These results suggest that ERbcx impact on
breast cancer progression may be post-transcriptional-
ly controlled. To explain the contradictory results of the
ERbcx significance in prognosis prediction, the follow-
ing possible causes have been proposed: ethnic differ-
ences, cellular localization of ERbcx [54], and cutoff val-
ues used for defining ERbcx positivity and type of sta-
tistical analysis [46]. Clearly, further studies using care-
fully standardised methods are needed to elucidate the
role of ERbcx in breast cancer pathology.
Thyroid hormone receptors (TRs) are encoded by
two genes, THRA and THRB. Due to alternative splic-
ing and different transcription start sites usage, several
TRa and TRb protein isoforms are produced [55]. Dis-
turbances in expression and functioning of TRs have
been identified in many types of cancer [56, 57]. In breast
cancer, apart from mutations, promoter hypermethy-
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lation and disturbed expression [58–60], impaired alter-
native splicing of TRs have been detected [61]. Altered
TRb1 transcripts had broad deletions in regions coding
DNA and ligand binding domains, and in the hinge
region involved in transcriptional co-repressor recruit-
ment. Such transcripts, if translated, would yield TRb1
proteins with seriously disturbed function.
Progesterone receptor gene PGR is transcribed into
two main isoforms, PR-A and PR-B, which are the re-
sult of the presence of two different functional promot-
Figure 2. Examples of disturbed alternative splicing in endocrine pathologies. A. Disturbed alternative splicing of KLF6 in prostate and
ovarian cancers. A IVS1-27: G/A polymorphism in intronic region of KLF6 gene leads to creation of an additional ESE binding site
specifically recognized by splicing factor SRp40. Binding of SRp40 results in activation of cryptic splice site located in exon 2 and
synthesis of alternatively spliced variant KLF6-SV1 with shortend exon 2 and out-of-frame exon 3 (dark). KLF6-SV1 activity leads to
downregulation of cyclin dependent kinase inhibitor p21, upregulation of antiapoptotic Bcl-2, and oncogenic c-myc, enhanced expression
of metalloproteinase MMP9, and degradation of proapoptotic protein NOXA. These changes result in increased survival and dissemination
of cancer cells. B. Disturbed alternative splicing of proinsulin in insulinoma [42]. NAT and SPV: alternatively spliced variants. Retention
of fragment of intron 1 in SPV variant results in changed 5’UTR resulting in enhanced translational efficiency, increased synthesis of
insulin protein and hyperinsulinemia. C. Alternative splicing of growth hormone in IGHD II (according to [66]). Mutation in exon 3
creates an additional binding site for SC35 and leads to enhanced skipping of exon 3. As a result, a short, 17.5 kDa GH protein isoform
is synthesized which is misfolded and accumulates in endoplasmic reticulum and finally leads to fragmentation of Golgi apparatus.
Rycina 2. Przykłady zaburzeń różnicowego składania pierwotnego transkryptu w patologiach endokrynnych. A. Zaburzony splicing
alternatywny transkryptu genu KLF6 w raku prostaty i jajnika. Polimorfizm IVS1-27: G/A w intronie genu KLF6 prowadzi do powstania
dodatkowego miejsca ESE wiążacego czynnik splicingowy SRp40. Wiązanie tego czynnika powoduje aktywację dodatkowego miejsca
splicingowego w eksonie 2 i powstanie alternatywnego wariantu KLF6-SV1 ze skróconym eksonem 2 i eksonem 3 z przesuniętą ramką
odczytu (zaznaczone ciemnym kolorem). KLF6-SV1 powoduje obniżenie ekspresji inhibitora p21 kinazy zależnej od cykliny, podwyższenie
ekspresji antyapoptotycznego białka Bcl-2, onkogenu c-myc i metaloproteinazy MMP9 oraz degradację proapoptotycznego białka NOXA.
W rezultacie prowadzi to do zwiększonej przeżywalności komórek nowotworowych i ich rozsiewu. B. Zaburzenie alternatywnego splicingu
proinsuliny w guzach insulinoma [42]. NAT i SPV: warianty splicingowe proinsuliny. Zatrzymanie fragmentu intronu 1 w wariancie
SPV powoduje zmianę sekwencji w rejonie 5’UTR, co skutkuje zwiększoną wydajnością translacji, nasiloną syntezą białka insulinowego
i hiperinsulinemią. C. Alternatywny splicing hormonu wzrostu w IGHDII (według [66]). Mutacja w eksonie 3 prowadzi do powstania
dodatkowego miejsca wiążącego czynnik splicingowy SC35, co skutkuje nasilonym wyłączaniem eksonu 3. W rezultacie powstaje krótki
wariant cząsteczki hormonu wzrostu, o wielkości 17,5 kDa i nieprawidłowej strukturze. Wariant ten gromadzi się w retikulum
endoplazmatycznym i prowadzi do fragmentacji aparatu Golgiego
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er regions [62]. PR-B protein is the longer one, and PR-
A protein lacks 164 amino acids of AF-3 (activation func-
tion-3) domain at the N-terminus. The primary tran-
script of PGR gene undergoes intensive alternative splic-
ing processing which results in additional PR variants
whose function is largely unknown. Hisatomi et al. [63]
identified a novel PR delta6/2 variant that was lacking
52 bp in exon 6, a region coding for ligand binding do-
main. PRdelta6/2 was expressed statistically significant-
ly more frequently in breast cancer tissues than in non-
cancerous paired controls. In other studies, multiple PR
variants with randomly deleted exons were found. How-
ever, their expression was not compared among normal
and cancerous tissues [64]. Hence, the role of PR splice
isoforms in breast cancer pathology is unknown and fu-
ture studies are needed to reveal their potential contri-
bution to tumour initiation and/or progression.
Isolated growth hormone deficiency type II
Isolated growth hormone deficiency type II (IGHD II)
is an autosomal dominant growth hormone deficiency
[65] which results mainly from aberrant alternative splic-
ing of pre-mRNA encoded by growth hormone gene
GH1. Alternative splicing of GH1 primary transcript
leads to synthesis of at least five protein isoforms. The
major product is a 22 kDa isoform exerting full biologi-
cal activity of growth hormone. The use of cryptic splice
site located in exon 3 leads to synthesis of a shorter,
20 kDa variant, which retains the activity of a normal
growth hormone molecule. When exon 3 is skipped
during alternative splicing, 17.5 kDa variant is produced
which acts as a dominant negative mutant and blocks
secretion of full-length protein. The residual two 11.3 kDa
and 7.4 kDa variants are produced in trace amounts.
Splice mutations identified in patients with IGHD II
result in increased production of 17.5 kDa GH variant
(Fig. 2C). These mutations affect splice sites at borders of
exon 3 or two ESEs located in exon 3. Skipping of exon
3 is regulated by two splicing factors, SF2/ASF and SC35,
which bind to ESE2. These two factors act antagonisti-
cally: binding of SF2/ASF prevents skipping of the exon,
while binding of SC35 leads to exclusion of exon 3 dur-
ing splicing. The mechanism of enhanced skipping of
exon 3 in IGHD II was elucidated by Solis et al. [66] who
found that mutation in exon 3 creates an additional
functional binding site for SC35 and thus leads to en-
hanced skipping of the exon and synthesis of 17.5 kDa
variant of growth hormone (Fig. 2C). This protein is
misfolded and accumulates in endoplasmic reticulum,
and subsequently leads to fragmentation of Golgi ap-
paratus, and in consequence, to disturbed trafficking
of GH and of other proteins [67].
Gonadal dysgenesis
Frasier syndrome (FS) is a rare disease characterized by
pseudohermaphroditism and progressive glomerulop-
athy. The phenotype includes gonadal dysgenesis and
normal female external genitalia in spite of XY karyo-
type. Child patients suffer from proteinuria which in-
creases with age leading to nephrotic syndrome and
development of end-stage renal failure in the second
or third decade of life. FS is associated with a high risk
of gonadoblastoma [68, 69]. FS is caused by disturbed
alternative splicing of WT1 gene transcript resulting
from mutations in splice site in exon 9 [70].
WT1 gene is located in 11p13 chromosome region
and encodes multifunctional protein which acts as a
transcription factor, and influences translation and al-
ternative splicing [71]. WT1, initially identified as Wilms
tumour suppressor gene, participates in multiple stag-
es of kidney development. WT1 gene comprises ten
exons, of which exons 7–10 encode DNA-binding do-
main composed of four zinc finger motifs. Alternative
splicing of WT1 primary transcript leads to synthesis of
four WT1 isoforms due to inclusion or skipping of ex-
ons 5 and 9. Inclusion of exon 9 results in incorporation
of a motif consisting of three amino acids, lysine-threo-
nine-serine (KTS), between the third and fourth zinc
fingers and leads to synthesis of +KTS isoform, in con-
trast to KTS variant which lacks the motif. In normal
human tissues the ratio of +KTS/–KTS isoforms is within
the range 1.10–1.49. In FS patients alternative splicing
of WT1 is disturbed due to heterozygous mutations in
donor splice site located in intron 9 which result in the
loss of +KTS isoform expression from one allele [70, 72].
As a result, the ratio of +KTS/–KTS isoforms decreases
to 0.5. Recently, Bradford et al. proposed a model by
which disturbed alternative splicing of WT1 leads to
development of Frasier syndrome [73]. Accordingly this
model, +KTS isoforms are regulators of expression of
Sry gene which is the sex-determining gene located on
the Y chromosome [74]. SRY protein is a transcription
factor which triggers differentiation of Sertoli cells.
These actions of SRY involve interactions with testis-
specific enhancer of Sox9 (TES) and lead to activation
of Sox9 transcription factor expression [75]. Using
knockout +KTS–/– mice, Bradford et al. [73] proposed
that +KTS isoform controls the expression of SRY which
subsequently triggers upregulation of Sox9. This in turn
induces expression of fibroblast growth factor 9 (FGF9)
which finally leads to differentiation of Sertoli cells.
FGF9 regulates differentiation of Sertoli cells via two
mechanisms. In pre-Sertoli cells in a feedback mecha-
nism FGF9 upregulates expression of Sox9 and this way
initiates differentiation. FGF9 induces also male-specific
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proliferation in the coelomic epithelium. Improper ra-
tio of +KTS/–KTS isoforms in Frasier syndrome patients
inhibits this pathway and leads to development of small
gonads with a number of pre-Sertoli cells insufficient
to ensure the proper development of testes.
Other pathologies
Since hormonal regulation is involved in wide physio-
logical processes, disturbed alternative splicing of tran-
scripts encoded by genes involved in endocrine regula-
tion is also found in non-endocrine diseases. This con-
cerns, for instance, the signalling pathway of thyroid hor-
mones which regulate key cellular processes including
proliferation, differentiation, apoptosis and metabolism
[76]. The human thyroid gland secretes hormones:
3,5,3',5'-tetraiodothyronine (thyroxine, T4) and 3,3',5-tri-
iodothyronine (T3) in a proportion defined by the T4/T3
ratio = 11:1 [77]. The majority of an active form of thy-
roid hormone, T3, is synthesized in extrathyroidal tis-
sues from T4 due to deiodination at the position 5’ of
phenolic ring. Deiodination reactions are catalysed by
enzymes called iodothyronine deiodinases. There are
three types of these enzymes. Type 1 deiodinase (Dio1)
is the only enzyme catalysing two types of deiodination
(5’ and 5) and is involved both in activation (synthesis of
T3) and inactivation (deiodination of T4 and T3) of TH.
Type 2 (Dio2) deiodinase is an activating enzyme
and catalyses deiodination at the position 5’ resulting
in synthesis of T3 from T4.
Type 3 deiodinase (Dio3) is an inactivating enzyme
which removes iodine at the position 5 of phenolic ring
of iodothyronines and is involved in deiodination of
T4 (yielding rT3) and T3 (yielding T2, diiodothyronine).
Type 3 deiodinases is encoded by an intronless gene
and therefore its primary transcript is not spliced. Type
1 and type 2 deiodinases are alternatively spliced; how-
ever, only one protein product of each gene is known
and the physiological role of their mRNA isoforms re-
mains unknown.
Variant disturbances of thyroid hormone receptors
and iodothyronine deiodinases are often found in dif-
ferent types of cancers [56, 57, 78–93]. These disturbanc-
es concern also alternative splicing and can lead to se-
vere pathological conditions, as in the aforementioned
case of disturbed alternative splicing of TRb2 leading to
thyroid hormone resistance in TSH-oma [13]. In kid-
ney cancer, disturbances of alternative splicing of un-
translated region (UTR) of TRb1 and of type 1 iodothy-
ronine deiodinase have been identified [78, 94]. UTR
variants of TRb1 differed in their predicted secondary
structure, translational efficiency and the presence or
absence of microRNA binding sites. In case of type 1
iodothyronine deiodinase, three splice isoforms were
cloned exclusively from tumour samples, suggesting
their potential use as cancer markers. The disturbances
of alternative splicing consisted of changes in ratios
between specific mRNA isoforms. A growing body of
evidence suggests that the ratios between splice iso-
forms contribute significantly to individual phenotype
variability and influence cellular homeostasis [95, 96].
A possible cause of alterations observed in kidney can-
cer can be improper expression of splicing factors whose
disturbed mRNA and protein level have been identi-
fied in tumours [78, 97].
Oestrogen receptors, ERa and ERb, are encoded by
two genes, ESR1 and ESR2, whose primary transcripts
undergo multiple alternative splicing events leading to
the synthesis of several splice variants [98]. Disturbed
alternative splicing of oestrogen receptors has been
linked to pathogenesis of Alzheimer’s disease (AD) and
schizophrenia. Ishunina and Swaab mapped the expres-
sion of ERa splice variants in the human brain and
found that distribution of mRNA isoforms was brain
area- and case-specific [99]. Moreover, in AD patients,
the number of ERa splice variants per brain area was
significantly diminished and the ratios between specif-
ic splice variants were changed. This difference was
more prominent in women than in men [99–101). The
most commonly detected was variant D7. This variant
is devoid of exon 7 which encodes a substantial part of
the ligand binding domain. Variant D7 acts as a domi-
nant negative ERa isoform. Several papers have sug-
gested that decreased oestrogen levels in the menopaus-
al period may be involved in the development of AD.
Moreover, it has been shown that oestrogen therapy
during menopausal transition is linked to a decreased
risk of AD and delayed development of the disease.
However, trials with oestrogen therapy in women with
diagnosed AD failed to show benefits on cognitive func-
tions [102]. Ishunina and Swaab suggested that high
expression of D7 in elderly healthy controls and AD pa-
tients may possibly explain reduced effects of oestro-
gen on cognitive functions [99]. Interestingly, this same
variant seems to be involved in the development of
major unipolar depression. In patients suffering from
this disease, the expression of D7 was 1.7 times more
frequent than in normal controls [103]. Since D7 vari-
ant inhibits oestrogen signalling mediated by the wild
type ERa, enhanced expression of D7 may change brain
oestrogen response in depression patients. These find-
ings are in agreement with observations that circulat-
ing levels of oestrogen correlate with symptoms of de-
pression [103].
In schizophrenia patients, multiple disturbances of
ERa at genomic and transcriptomic level have been
found, including altered frequency of splice variants and
detection of an abnormally spliced transcript with re-
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tained intronic sequence [103]. It was shown that the
transcriptional activity of ERa is modulated by a ErbB4-
-ICD protein, belonging to the leading schizophrenia
susceptibility pathway [104]. ErbB4 is a receptor with
tyrosine kinase activity whose activation leads to its
cleavage and release of the transcriptionally active in-
traplasmic domain (ErbB4-ICD). ErbB4-ICD enhances
ERa mediated transcriptional activation. However, this
effect is inhibited by the presence of D7 splice variant,
suggesting that D7 functions as a dominant negative
variant that suppresses ERa mediated oestrogen signal-
ling [104].
Alternative splicing in diagnostics
and therapy
Evidence of the disturbed alternative splicing in differ-
ent pathologies raised an idea of using specific splice
variants as diagnostic markers or targets for therapeu-
tic actions. The most efficient method for searching for
specific splicing markers is global transcriptomic analy-
sis followed by verification using reverse transcription
PCR. Klinck et al. [105] proposed a new approach which
they called layered and integrated system for splicing
annotation (LISA) based on direct high-throughput re-
verse transcription-PCR validation of alternative splic-
ing events. Using this method, they analyzed splicing
of 600 cancer-related genes in ovarian cancer samples
and discovered 48 highly cancer-specific splicing events
that created a molecular signature of epithelial ovarian
cancer. The same approach used for analysis of breast
cancer samples allowed for identification of cancer tis-
sues with 96% accuracy and ordering of cancer sam-
ples according to histopathological grade [106]. New
data on cancer-specific splicing markers can be identi-
fied using mouse models as shown by Menon et al. [107].
Using mass spectra derived from the plasma proteome
of mouse model of human pancreatic ductal adenocarci-
noma, they identified a pattern of splice isoforms, includ-
ing novel and differentially expressed variants that al-
lowed for differentiating tumour-bearing and control
mice. Thus, the study provided a basis for a noninvasive
assay of candidate biomarkers for pancreatic cancer.
Pro- or antiproliferative activity of different splicing
variants offers an opportunity for manipulations aim-
ing for therapeutic effects. For instance, antisense oli-
gonucleotide induced shift in alternative splicing of Bcl-
x pre-mRNA resulted in increased expression of proap-
optotic Bcl-xS isoform, sensitized breast and prostate
cancer cells to several antineoplastic agents and radia-
tion, and promoted apoptosis of multidrug-resistant
MCF-7/ADR breast cancer cell line [108].
Since alternative splicing events are tightly regulat-
ed by splicing factors and elements of spliceosome, there
is growing interest in compounds targeting these pro-
teins to achieve antiproliferative effects. Some of these
compounds, such as pladienolides, are currently being
tested in clinical trials in Europe and the United States
[109, 110]. Pladienolide is an antitumour macrolide pro-
duced by Streptomyces platenensis that targets SF3b splic-
ing factor complex, and which leads to accumulation of
unspliced or incompletely spliced primary transcripts
[2007]. The effects of modulated expression of splicing
factors in cancer cells can be especially promising in case
of proteins that exert oncogenic properties. This was
shown for SF2/ASF splicing factor which belongs to the
serine-arginin rich family of proteins. Karni et al. proved
that overexpression of SF2/ASF results in transforma-
tion of immortal rodent fibroblasts which form sarco-
mas in nude mice. Conversely, knockdown of SF2/ASF
led to reduction of tumour volume [9].
Summary
Alternative splicing is a process of crucial importance
for the proper function of cells, including those involved
in hormonal signalling. Future studies using global anal-
ysis of transcript variants and splicing regulatory pro-
teins would certainly provide further data for under-
standing the molecular basis of multiple endocrine pa-
thologies. Knowledge of specific mechanisms initiated
by improperly spliced transcripts will offer opportuni-
ties for new diagnostic and therapeutic approaches. The
most challenging seems to discriminate between indi-
vidually-specific splicing variances and changes result-
ing from disease. Therefore, apart from employing tools
for global analysis at transcriptomic and proteomic level,
studies on large numbers of samples from patients are
needed.
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